These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 24519954)

  • 1. Analysis of safety data in clinical trials using a recurrent event approach.
    Gong Q; Tong B; Strasak A; Fang L
    Pharm Stat; 2014; 13(2):136-44. PubMed ID: 24519954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Graphical approaches to the analysis of safety data from clinical trials.
    Amit O; Heiberger RM; Lane PW
    Pharm Stat; 2008; 7(1):20-35. PubMed ID: 17323410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Competing time-to-event endpoints in cardiology trials: a simulation study to illustrate the importance of an adequate statistical analysis.
    Rauch G; Kieser M; Ulrich S; Doherty P; Rauch B; Schneider S; Riemer T; Senges J
    Eur J Prev Cardiol; 2014 Jan; 21(1):74-80. PubMed ID: 22964966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of multivariate recurrent event data with time-dependent covariates and informative censoring.
    Zhao X; Liu L; Liu Y; Xu W
    Biom J; 2012 Sep; 54(5):585-99. PubMed ID: 22886587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Summarizing the incidence of adverse events using volcano plots and time intervals.
    Zink RC; Wolfinger RD; Mann G
    Clin Trials; 2013; 10(3):398-406. PubMed ID: 23690094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sample size calculation in survival trials accounting for time-varying relationship between noncompliance and risk of outcome event.
    Li B; Grambsch P
    Clin Trials; 2006; 3(4):349-59. PubMed ID: 17060209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tests for multivariate recurrent events in the presence of a terminal event.
    Chen BE; Cook RJ
    Biostatistics; 2004 Jan; 5(1):129-43. PubMed ID: 14744832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-parametric inference of adverse events under informative censoring.
    Nishikawa M; Tango T; Ogawa M
    Stat Med; 2006 Dec; 25(23):3981-4003. PubMed ID: 16526008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonparametric estimation for cumulative duration of adverse events.
    Wang J; Quartey G
    Biom J; 2012 Jan; 54(1):61-74. PubMed ID: 22170311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statistical methods to analyze adverse events data of randomized clinical trials.
    Siddiqui O
    J Biopharm Stat; 2009 Sep; 19(5):889-99. PubMed ID: 20183450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The FDA outlook of events reporting after ticagrelor or clopidogrel in the PLATO Trial: impact of sponsor censoring dates, drug discontinuation, and withdrawal of consent.
    Serebruany VL
    Cardiology; 2011; 120(3):169-71. PubMed ID: 22418766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multivariate frailty models for two types of recurrent events with a dependent terminal event: application to breast cancer data.
    Mazroui Y; Mathoulin-Pélissier S; Macgrogan G; Brouste V; Rondeau V
    Biom J; 2013 Nov; 55(6):866-84. PubMed ID: 23929494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analyzing semi-competing risks data with missing cause of informative terminal event.
    Zhou R; Zhu H; Bondy M; Ning J
    Stat Med; 2017 Feb; 36(5):738-753. PubMed ID: 27813148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methods for multivariate recurrent event data with measurement error and informative censoring.
    Yu H; Cheng YJ; Wang CY
    Biometrics; 2018 Sep; 74(3):966-976. PubMed ID: 29441520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cumulative incidence in competing risks data and competing risks regression analysis.
    Kim HT
    Clin Cancer Res; 2007 Jan; 13(2 Pt 1):559-65. PubMed ID: 17255278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meta-analysis of incidence of rare events.
    Lane PW
    Stat Methods Med Res; 2013 Apr; 22(2):117-32. PubMed ID: 22218366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II cancer clinical trials with a one-sample log-rank test and its corrections based on the Edgeworth expansion.
    Sun X; Peng P; Tu D
    Contemp Clin Trials; 2011 Jan; 32(1):108-13. PubMed ID: 20888929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensitivity analyses for informative censoring in survival data: A trial example.
    Liu Y
    J Biopharm Stat; 2017; 27(4):595-610. PubMed ID: 27010683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Data mining and statistically guided clinical review of adverse event data in clinical trials.
    Southworth H; O'Connell M
    J Biopharm Stat; 2009 Sep; 19(5):803-17. PubMed ID: 20183445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cumulative incidence rate of medical consultation for fecundity problems--analysis of a prevalent cohort using competing risks.
    Duron S; Slama R; Ducot B; Bohet A; Sørensen DN; Keiding N; Moreau C; Bouyer J
    Hum Reprod; 2013 Oct; 28(10):2872-9. PubMed ID: 23838160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.